394.80
+0.10%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ypsomed Holding
Its shares trade on SIX under the ticker YPSN.SW. It has been listed since 22 September 2004. In the fiscal year to 31 March 2026, it reported revenue of CHF 731.0m and net income of CHF 221.9m. At that date it held total assets of CHF 1.35bn and shareholders' equity of CHF 748.1m.
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. The company is headquartered in Burgdorf, Bern. The company went IPO on 2004-09-22. The firm develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The firm operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The firm operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 22 Sept 2004
- Employees
- 1,714
Leadership
Pay as last reported
- Mr. Gilbert AchermannNon-Executive Independent Chairman of the BoardCHF 275,300
- Mr. Simon MichelChief Executive Officer, Executive Director, Member of the Executive Board, since 2008CHF 1.2m
- Mr. Paul FonteyneNon-Executive Independent Vice Chairman of the BoardCHF 139,400
- Mr. Samuel KunzliChief Financial Officer, Member of the Executive Board
- Mr. Frank MengisChief Operating Officer, Member of the Executive Board
- Dr. Nicolas MeyerMember of the Executive Board, Chief Legal Officer, Secretary of the Board of Directors
- Ms. Ulrike BauerMember of the Executive Board, Chief Business Officer Ypsomed Delivery Systems
- Mr. Sebastien DelariveMember of the Executive Board, Chief Executive Officer of Ypsomed Diabetes Care AG
- Mr. Michael ZauggChief Corporate Officer, Member of the Executive Board
- Ms. Marie-Pierre ZerrDirector
- Dr. Martin MuenchbachNon-Executive Independent DirectorCHF 161,600
- Mr. Thomas KuttHead of Investor Relations, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 95
- Social
- 79
- Governance
- 42
- Direct emissions (scope 1)
- 2,557 t
- Energy emissions (scope 2)
- 1 t
- Value chain emissions (scope 3)
- 84,867 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ypsomed Holding AG has several strengths that contribute to its success in the market. These include:
- However, Ypsomed Holding AG also faces certain weaknesses that need to be addressed for sustained success:
- Ypsomed Holding AG has several opportunities to further expand and grow its business:
- Ypsomed Holding AG should be mindful of the following threats in the market:
Weaknesses
- However, Ypsomed Holding AG also faces certain weaknesses that need to be addressed for sustained success:
- Ypsomed Holding AG has several opportunities to further expand and grow its business:
- Ypsomed Holding AG should be mindful of the following threats in the market:
Opportunities
- Ypsomed Holding AG has several opportunities to further expand and grow its business:
- Ypsomed Holding AG should be mindful of the following threats in the market:
Threats
- Ypsomed Holding AG should be mindful of the following threats in the market:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.